All subjects received pre-travel counseling and were provided antibiotics and antidiarrheals (loperamide) for use only if TD developed. The subjects were blinded and randomized to take two capsules of placebo or oral synbiotic (a combination of two probiotics and a prebiotic) called Agri-King Synbiotic (AKSB) beginning 3 days prior to departure, daily while traveling, and for 7 days after return. All subjects kept symptom and medication Selleck Mitomycin C diaries and submitted a stool sample for pathogen carriage

within 7 days of return. The study was powered to detect a 50% reduction in the incidence of TD. Of the 196 adults (over 18 years of age) enrolled in the study, 54.3% were female and 80.9% were younger than 60 years. The study randomized 94 people to the AKSB arm and 102 to placebo. The incidence of TD was 54.5% in the overall group with 55.3% in the AKSB arm and 53.9% in the placebo (p = 0.8864). Among the subjects who experienced

diarrhea (n = 107) there was no significant difference in the proportion of subjects that took antibiotics versus those that did not take antibiotics (35% vs 29%, p = 0.68). AKSB was safe with no difference in toxicity between the two arms. The prophylactic oral synbiotic was safe but did not reduce the risk of developing TD among travelers, nor did it decrease the duration of TD or the use of antibiotics when TD occurred. Travelers’ diarrhea (TD) is associated with significant morbidity and a decrease in quality of life for international travelers.[1] Symptoms of TD are usually self-limited and resolve within a week. 3-MA manufacturer MRIP It is estimated that 20% to 50% of people traveling to developing areas will develop TD.[2] TD is defined by more than three loose stools per day with or without associated symptoms of fever, nausea, or abdominal pain.[3] It is typically caused by bacterial pathogens such as enterotoxigenic Escherichia coli, enteroaggregative E coli, Campylobacter

species, Shigella species, or Salmonella species. Prevention of TD relies on food and water precautions. Primary prevention of TD using antimicrobials such as fluoroquinolones,[4] rifaximin,[5, 6] or non-antibiotic strategies such as bismuth subsalicylate (Pepto-Bismol)[7, 8] are effective but are typically reserved for high-risk populations, such as severely immunosuppressed patients. Use of these agents is also restricted owing to cost, emerging antimicrobial resistance, and dosing complexity (eg, bismuth subsalicylate is best taken as two tablets every 6 hours). Travelers are often provided with antimicrobials and loperamide to self-treat severe diarrhea, should it occur. Self-treatment of TD with antibiotics (often fluoroquinolones or azithromycin) reduces the duration of symptoms to 1 to 2 days.[9] However, with increasing travel and antimicrobial resistance, it is important to identify non-antimicrobial-based preventive strategies, such as probiotics, to prevent or treat TD.